AGM, page-63

Can I just add that for the benefit of investors who couldn’t attend and speak to Wayne themselves the following is what was discussed or asked by others

-Takeover
-German study surrounding use of CardioCel in aortic valve repair ( which didn’t show CardioCel in a good light)
-product pipeline
-delay on TGA approval
-perceived slow take up of cardiocel flat patch
-partnership for TAVR ( potential)
- competitors dirty tricks
Can I say I am sleeping very well tonight. I must add that from time to time we have posters that come across very confident of what is happening behind the scenes when really they have no clue. The employees working for this company are doing the biz every day and I must say they are so confident of the path they are travelling.
As a example if we look at the TAVR device
WP is so bullish on this aspect. They have surrounded themselves with experts in the advisory board that assisted the other companies to get their TAVR device to market. These are companies which arguably dont have the clinical data on calcification and textile strength we have. Anyway I think you get the idea.
IMO